We serve Chemical Name:2,6-DIPHENYL-4-(2,4,6-TRIPHENYL-1-PYRIDINIO)PHENOLATE CAS:10081-39-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,6-DIPHENYL-4-(2,4,6-TRIPHENYL-1-PYRIDINIO)PHENOLATE
CAS.NO:10081-39-7
Synonyms:2,6-diphenyl-4-(2,4,6-triphenylpyridin-1-ium-1-yl)phenolate;MFCD00013355
Molecular Formula:C41H29NO
Molecular Weight:551.67500
HS Code:2933399090
Physical and Chemical Properties:
Melting point:271-275ºC(lit.)
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:26.94000
Exact Mass:551.22500
LogP:10.44210
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 2,6-diphenyl-4-(2,4,6-triphenylpyridin-1-ium-1-yl)phenolate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00013355 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00013355 Use and application,2,6-diphenyl-4-(2,4,6-triphenylpyridin-1-ium-1-yl)phenolate technical grade,usp/ep/jp grade.
Related News: In the current trial, a total of 196 patients were randomly chosen to receive either the vaccine or a placebo. 2,6-DIPHENYL-4-(2,4,6-TRIPHENYL-1-PYRIDINIO)PHENOLATE manufacturer However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future. 2,6-DIPHENYL-4-(2,4,6-TRIPHENYL-1-PYRIDINIO)PHENOLATE supplier Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 2,6-DIPHENYL-4-(2,4,6-TRIPHENYL-1-PYRIDINIO)PHENOLATE vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 2,6-DIPHENYL-4-(2,4,6-TRIPHENYL-1-PYRIDINIO)PHENOLATE factory In the current trial, a total of 196 patients were randomly chosen to receive either the vaccine or a placebo.
